VIP943

N/A

Report date: 2024/02/05 14:02:00

Base Information

Drug NameVIP943
Drug Alias NameIL3RA-KSPi-ADCBAY-943VIP-943
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer AGVincerx Pharma Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A